Neovacs S.A SMA 50
¿Qué es el SMA 50 de Neovacs S.A?
El SMA 50 de Neovacs S.A. es €0 +100.00%
¿Cuál es la definición de SMA 50?
SMA 50 es un precio promedio de las acciones de los últimos 50 días calculado como una media no ponderada de los previos 50 precios de cierre de acciones.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 de compañías en Sector Health Care en EURONEXT en comparadas con Neovacs S.A
¿Qué hace Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Empresas con sma 50 similar a Neovacs S.A
- Neovacs S.A tiene SMA 50 de €0 +100.00%
- EVmo Inc tiene SMA 50 de $0 +99.75%
- Blue Capital Reinsurance Ltd tiene SMA 50 de $0 -Inf%
- Kaleido Biosciences Inc tiene SMA 50 de $0 +59.40%
- Yangtze River Port and Logistics Ltd tiene SMA 50 de $0 +28.25%
- iFresh Inc tiene SMA 50 de $0 +0.00%
- Aridis Pharmaceuticals Inc tiene SMA 50 de $0 +83.25%